Please assess the completion status of the following clinical trial:

Trial Title: Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Requires treatment with IV antibiotic therapy for hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)~* Fulfills clinical and radiographic criteria, with onset of criteria occurring after more than 48 hours of hospitalization or within 7 days after discharge from a hospital (for HABP); or at least 48 hours after mechanical ventilation (for VABP)~* Has an adequate baseline lower respiratory tract specimen obtained for Gram stain and culture~* Has an infection known or thought to be caused by microorganisms susceptible to the IV study therapy~* Agrees to allow any bacterial isolates obtained from protocol-required specimens related to the current infection to be provided to the Central Microbiology Reference Laboratory for study-related microbiological testing, long term storage, and other future testing~* Is not of reproductive potential; or if of reproductive potential agrees to avoid impregnating a partner or avoid becoming pregnant, by practicing abstinence or using acceptable contraception~Exclusion Criteria:~* Has a baseline lower respiratory tract specimen Gram stain that shows the presence of Gram-positive cocci only~* Has confirmed or suspected community-acquired bacterial pneumonia (CABP)~* Has confirmed or suspected pneumonia of viral, fungal or parasitic origin~* Has HABP/VABP caused by an obstructive process, including lung cancer or other known obstruction~* Has a carcinoid tumor or carcinoid syndrome~* Has active immunosuppression defined as either receiving immunosuppressive medications or having a medical condition associated with immunodeficiency~* Is expected to survive for less than 72 hours~* Has a concurrent condition or infection that would preclude evaluation of therapeutic response~* Has received effective antibacterial drug therapy for the index infection of HABP/VABP for more than 24 hours continuously, during the previous 72 hours~* Has a history of serious allergy, hypersensitivity or a serious reaction to any penicillin or beta-lactamase inhibitors~* Female is pregnant, expecting to conceive, is breastfeeding or plans to breastfeed~* Has a history of seizure disorder requiring ongoing prior treatment with anti-convulsive therapy within the last 3 years~* Anticipates treatment with the following: valproic acid or divalproex sodium, serotonin re-uptake inhibitors, tricyclic antidepressants, or serotonin receptor antagonists, meperidine, buspirone, concomitant systemic antibacterial agents, antifungal or antiviral therapy for the index infection of HABP/VABP~* Is currently undergoing hemodialysis or peritoneal dialysis~* Is currently participating in, has participated in during the previous 30 days, or anticipates to participate in any other clinical study involving the administration of experimental medication~* Has previously participated in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMI/REL (Type: EXPERIMENTAL): Imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a FDC administered intravenously (IV) every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
- PIP/TAZ (Type: ACTIVE_COMPARATOR): Piperacillin 4000 mg + tazobactam 500 mg as a FDC administered IV every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).